Upcoming FDA Approval Will Open New Oncology Avenues

Published
27 Mar 25
Updated
14 Aug 25
AnalystConsensusTarget's Fair Value
US$27.00
72.8% undervalued intrinsic discount
14 Aug
US$7.34
Loading
1Y
-61.9%
7D
32.5%

Author's Valuation

US$27.0

72.8% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on01 May 25
Fair value Decreased 18%

Shared on24 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25
Fair value Increased 4.91%

AnalystConsensusTarget has decreased profit margin from 19.3% to 17.3%.

Shared on09 Apr 25
Fair value Decreased 3.63%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Increased 26%

AnalystConsensusTarget has increased profit margin from 10.5% to 19.3%, decreased future PE multiple from 91.0x to 67.6x and decreased shares outstanding growth rate from 0.1% to 0.1%.